Consideration of breast cancer subtype in targeting the androgen receptor
Under a Creative Commons license
open access
Keywords
Breast cancer
Androgen receptor
AR antagonist
Estrogen receptor
Human epidermal growth factor receptor 2
Triple-negative breast cancer
Abbreviations
AR
androgen receptor
CBR
clinical benefit rate
CI
confidence interval
DFS
disease-free survival
DHT
dihydrotestosterone
ER
estrogen receptor
HR
hazard ratio
HER2
human epidermal growth factor receptor 2
HER3
human epidermal growth factor receptor 3
HR
hormone receptor
IHC
immunohistochemistry
LAR
luminal androgen receptor
LHRH
luteinizing hormone-releasing hormone
NA
not available
OS
overall survival
PFS
progression-free survival
PR
progesterone receptor
TNBC
triple-negative breast cancer
Wnt
Wingless protein
Cited by (0)
© 2019 The Authors. Published by Elsevier Inc.